Will the Death of Patient with ALS Prompt Biogen to Improve Access to Experimental Drugs?

Lisa Stockman Mauriello passed away earlier this month after an intense fight to use Biogen’s experimental drug for Amyotrophic Lateral Sclerosis (ALS), Tofersen. Her passing is seen as a call for pharmaceutical companies to improve access to drugs used in rare diseases, especially in patients facing bleak outcomes.

“It’s been two weeks since Lisa Stockman Mauriello passed away and a lingering question, in my mind, is whether she died in vain. I’d like to think not.” Read more here.

(Source: Ed Silverman, STAT News, 8/19/21)